Filing Flows › Industrials › Revvity (RVTY)
Revvity (RVTY) earnings and revenue breakdown
Latest: Q3 2026 · 8-K filed Nov 3, 2026
Q3 2026 Revenue up 4% year over year to $729M · 9¢ of every $1 of revenue kept as net profit · operating margin 10.6%
Revvity made $729M in Q3 2026 (+4% Y/Y): Life Sciences $380M, Diagnostics $349M. Operating margin 10.6%, net earnings $62.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 8-K filed Nov 3, 2026 (preliminary, from the earnings release).
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $728.9M in Q3 2026, up 4% year over year and roughly flat from the previous quarter. Life Sciences was the largest line at 52% of revenue. Life Sciences added $36.8M year over year (up 11%), 123% of the total change. Diagnostics declined 2%.
Operating profit was $77.4M, a 10.6% margin (down 1.1 points year over year). Operating profit fell $4.5M even though revenue rose $29.9M versus Q3 2025, so costs grew faster than sales. Total costs grew 6% against revenue growth of 4%. The fastest-growing cost line was SG&A (+14%). Net earnings were $62.3M, up 34% year over year. The effective tax rate was 19.5%.
Operating cash flow was $166.7M (up 20% year over year), 268% of net earnings. Non-cash charges added back $102.9M of depreciation and amortization and $9.8M of share-based compensation. Capital expenditures of $14.3M left free cash flow of $152.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 8-K | Nov 3, 2026 | $729M | +4% | 10.6% | $62.3M | $167M |
| Q2 2026 | 10-Q | Aug 11, 2026 | $730M | +1% | 12.2% | $51.8M | $192M |
| Q1 2026 | 10-Q | May 12, 2026 | $711M | +7% | 10.7% | $40.7M | $115M |
| Q4 2025 | 10-K | Feb 24, 2026 | $772M | +6% | 14.5% | $98.4M | $182M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $699M | +2% | 11.7% | $46.7M | $138M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $720M | +4% | 12.6% | $53.9M | $134M |
| Q1 2025 | 10-Q | May 6, 2025 | $665M | +2% | 10.9% | $42.2M | $128M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Revvity
We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees. Our common stock is listed on the New York Stock Exchange under the symbol “RVTY” and we are a component of the S&P 500 Index.
In its own words, from its 10-K, filed Feb 24, 2026.
Revvity against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +4% against the peers' median +4%. Operating margin: 10.6% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
| TXG 10x Genomics | Q3 2026 | $151M | +1% | -10.7% |
Source: Revvity 8-K on SEC EDGAR · CIK 31791 · Laboratory Analytical Instruments
Guidance and outlook
13F: who owns RVTY and who is buying
More on RVTY
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results